Linked Life Data

19839938

Source:http://linkedlifedata.com/resource/pubmed/id/19839938

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2010-4-14
pubmed:abstractText
The treatment against cancer is being flooded by targeted therapies. Imatinib mesylate (Gleevec) was the first molecule to provide the proof of principle that targeting an aberrant tyrosine kinase responsible for the uncontrolled cell cycle progression allows for the eradication of tumors. The ideal targeted therapy should eliminate the molecular event responsible for the disease, an oncogenic product such as c-KIT, ABL/BCR and PDGFRa in the case of Gleevec. Two issues related to this conceptual advance are raised in clinical practice. First, these therapies might target additional pathways generating side effects. Secondly, non tumoral cells bearing the molecular target might respond and induce additional biological outcomes. This review will summarize the by-stander immune modulations promoted by the paradigmatic compound Gleevec, leading to unexpected new therapeutic indications.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1871-5303
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1-7
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties.
pubmed:affiliation
Centre d'Investigation Clinique en Biothérapie, CICBT, Villejuif, France.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't